Levetiracetam Bluepharma

Levetiracetam, the active ingredient in Levetiracetam Bluepharma, is an anticonvulsant presented as an oral tablet for oral use. It is employed to control partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy. The medication is approved in the European Union and is supplied in a standard dosage strength.

GNH USA supplies Levetiracetam Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures reliable delivery and regulatory compliance across multiple markets.

Levetiracetam is an anticonvulsant indicated for several seizure types. - Partial seizures: reduces frequency of focal onset seizures. - Generalized tonic-clonic seizures: helps prevent convulsive episodes. - Myoclonic seizures: decreases occurrence of sudden muscle jerks.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Major depression or mood swings - Rash with systemic involvement - Blood dyscrasias such as neutropenia or thrombocytopenia

When prescribing levetiracetam, clinicians should consider several safety precautions. - Pregnancy: Category B; use only if potential benefit justifies the risk. - Renal impairment: dose adjustment may be necessary based on creatinine clearance. - Psychiatric symptoms: monitor for mood changes, depression, or agitation. - Concomitant CNS depressants: may increase sedation or dizziness. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce levetiracetam plasma concentrations. - Alcohol: can enhance central nervous system depression and increase side‑effect risk. - Co‑administration with other antiepileptics that have overlapping toxicity: may require careful monitoring.

Moderate Interactions (Monitor Closely): - Acetazolamide: may increase levetiracetam levels, necessitating dose review. - Renally cleared drugs (e.g., aminoglycosides): monitor renal function to avoid accumulation. - Oral contraceptives: levetiracetam may reduce hormonal efficacy, consider alternative contraception.